BETonMACE: Negative Trial, but 'Cautious Optimism' on Apabetalone
Medscape,
PHILADELPHIA — The investigational drug apabetalone (Resverlogix) did not reduce the risk for major adverse cardiovascular…
PHILADELPHIA — The investigational drug apabetalone (Resverlogix) did not reduce the risk for major adverse cardiovascular…
PHILADELPHIA — The investigational drug apabetalone (Resverlogix) did not reduce the risk for major adverse cardiovascular…
Philadelphia – Der BET-Inhibitor Apabetalon erreichte in der Phase-3-Studie BETonMACE den primären Endpunkt nicht.
The phase III trial failed to meet its primary endpoint, but some hold out hope for this new drug class in other populations.